Why Pediatric Clinical Evaluation Fails Before It Even Starts

Written by HATEM RABEH, MD, MSc Ing

Your Clinical Evaluation Expert And Partner

in
S

Pediatric indications are not a subset of adult indications. They are a distinct regulatory and clinical challenge. Yet many manufacturers approach pediatric clinical evaluation as if it were an addendum to adult work. This is where deficiencies originate.

The MDR does not provide a dedicated article for pediatric devices. But it does require that clinical evaluation addresses the intended patient population. When that population includes children, the scope and rigor of the evaluation change fundamentally.

This is not about adding a paragraph on children. It is about building an entire evaluation around developmental physiology, ethical constraints, and scarcity of data.

The Core Misconception

Most manufacturers believe that if adult clinical data shows safety and performance, pediatric use can be justified with scaling adjustments or conservative labeling.

This fails because children are not pharmacokinetically, anatomically, or cognitively scaled-down adults. A device that performs safely in a 70 kg adult may produce entirely different tissue reactions, infection rates, or usability failures in a 15 kg child.

Reviewers know this. When they see extrapolation without developmental justification, they stop reading the rest of the report.

What the MDR Actually Requires

MDR Annex XIV Section 1 requires that clinical evaluation addresses all intended patient groups. When pediatrics is an intended use, the clinical evaluation must demonstrate that the device meets its intended purpose specifically in children.

This means:

The benefit-risk profile must be established for the pediatric population separately. The literature review must prioritize pediatric-specific studies. Equivalent device analysis must account for age-related anatomical and physiological differences. PMCF must include pediatric subgroup analysis if children are part of the post-market population.

These are not recommendations. They are expectations that emerge during every competent review.

Age Stratification and Physiological Differences

Here is where many evaluations collapse. Pediatrics is not one population. It spans neonates, infants, toddlers, children, and adolescents. Each group has distinct physiology.

A vascular access device designed for adults may have different insertion risks, thrombosis rates, and infection profiles in a neonate compared to a 12-year-old. Wound healing differs. Immune response differs. Even the mechanical environment differs due to growth and activity patterns.

If your clinical evaluation does not stratify by age and address these differences, the reviewer will conclude you do not understand your own device risks.

I have reviewed files where manufacturers grouped all patients under 18 into one category. This is not stratification. This is avoidance.

The Data Scarcity Problem

Pediatric clinical data is scarce. Regulatory and ethical constraints limit the ability to conduct pediatric trials. Most manufacturers face this reality and then make a critical error: they interpret scarcity as permission to lower the evidence standard.

Scarcity does not reduce the requirement. It changes the strategy.

When direct pediatric clinical data is unavailable, the clinical evaluation must rely on:

Literature from similar devices used off-label in pediatrics. Biomechanical modeling or computational simulations adapted for pediatric anatomy. Pediatric preclinical testing in age-appropriate animal models. Post-market surveillance from comparable devices with pediatric use.

But all of this must be explicitly justified. The report must explain why each alternative data source is relevant and how it compensates for the absence of direct pediatric trials.

Silence on data scarcity is interpreted as data absence.

The Ethical and Regulatory Layer

Pediatric device use is governed by ethical principles that extend beyond the MDR. Informed consent involves parents or guardians. Assent may be required from older children. The concept of minimal risk is interpreted differently.

These ethical considerations directly influence your clinical evaluation. If your device requires invasive procedures, the threshold for demonstrating benefit becomes higher. If the device is used in vulnerable neonates, the margin for acceptable risk becomes narrower.

Reviewers assess whether you understand these ethical boundaries. If the clinical evaluation presents pediatric use as equivalent to adult use without addressing vulnerability, safeguarding, or proportionality, the file is rejected.

I have seen evaluations that mention pediatric use in the intended purpose but include no discussion of ethical justification, parental involvement, or risk mitigation specific to vulnerable populations.

This signals to the reviewer that the manufacturer has not engaged with the real-world implications of pediatric use.

Literature Review for Pediatrics

The literature search strategy must explicitly target pediatric populations. This means using age-specific search terms and stratifying results by pediatric age groups.

Many manufacturers run a single literature search and then extract pediatric subsets from studies that were primarily adult-focused. This is insufficient.

The search must prioritize:

Pediatric-specific clinical trials. Case series and registries reporting pediatric outcomes. Off-label use studies in children. Comparative studies analyzing pediatric versus adult outcomes for similar devices.

When pediatric literature is limited, the report must document this limitation explicitly and describe how the gap is addressed through other evidence.

But again, scarcity is not an excuse. It is a reality that requires compensatory rigor.

Equivalence Claims in Pediatric Contexts

Some manufacturers attempt to claim equivalence to a device used in adults and extend the claim to pediatrics. This rarely survives review.

Equivalence under MDR requires clinical, technical, and biological equivalence. When the patient population shifts to pediatrics, biological equivalence is disrupted.

A suture used in adult wound closure may be equivalent to another adult suture. But when applied to a neonate with thinner skin, faster metabolism, and different healing kinetics, the equivalence claim becomes questionable.

If you intend to use equivalence for pediatric indications, the equivalent device must have documented pediatric use, and your evaluation must demonstrate that the differences between devices do not affect pediatric safety or performance.

Most manufacturers cannot meet this standard. They default to claiming equivalence based on adult data and hope the reviewer does not notice the gap.

Reviewers always notice.

PMCF and Pediatric Subgroups

Post-market clinical follow-up for pediatric devices must include specific plans for monitoring pediatric outcomes. If your device is used across adult and pediatric populations, your PMCF plan must stratify data collection by age group.

This includes:

Adverse event reporting segmented by pediatric age categories. Long-term outcome tracking for growth-related complications. Device-specific risks such as outgrowing implants or age-dependent failure modes.

PMCF for pediatrics is not the same as general PMCF with children included. It is targeted surveillance designed to capture age-specific risks that may not emerge in adult populations.

When a PMCF plan treats pediatrics as a footnote, it signals to the reviewer that post-market safety monitoring is inadequate.

What a Strong Pediatric Clinical Evaluation Looks Like

A well-constructed pediatric clinical evaluation begins with a clear definition of the pediatric age groups included in the intended use. It stratifies risks by developmental stage. It identifies physiological differences that affect device performance.

The literature review is targeted and comprehensive. When pediatric data is scarce, the report documents alternative evidence sources and justifies their relevance.

If equivalence is claimed, the evaluation demonstrates that the equivalent device has documented pediatric use and that any differences do not compromise safety or performance in children.

The benefit-risk analysis is conducted separately for pediatric populations. It accounts for vulnerability, ethical considerations, and long-term developmental outcomes.

Finally, the PMCF plan includes specific pediatric surveillance activities, with data collection stratified by age group.

This is not a checklist. This is the reasoning structure that makes pediatric clinical evaluation defensible.

Final Thought

Pediatric clinical evaluation is not adult evaluation with adjustments. It is a separate evaluation informed by developmental biology, ethical principles, and the recognition that children are not small adults.

When manufacturers treat pediatric indications as an extension rather than a distinct challenge, the evaluation fails before the first review.

The question is not whether pediatric data exists. The question is whether your evaluation demonstrates that you understand the pediatric population well enough to justify device use in children.

That understanding must be visible in every section of the report.

Peace,
Hatem
Clinical Evaluation Expert for Medical Devices
Follow me for more insights and practical advice.